{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:42:02Z","timestamp":1793295722267,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018286","name":"Dutch Arthritis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018286","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ZonMW"},{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      This study aimed to assess the quantitative uptake of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT in the lungs of patients with early severe diffuse cutaneous systemic sclerosis (SSc) with and without interstitial lung disease (ILD), compared to controls. In patients with SSc-ILD,\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake was correlated to high-resolution computed tomography (HRCT) and pulmonary function test (PFT) parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective, cross-sectional study was conducted, involving 15 patients with SSc-ILD, 5 patients with SSc without ILD, and 7 controls without SSc.\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT scans were performed following standardized protocols, and quantitative analysis of tracer uptake was conducted in predefined lung regions. In addition, HRCT scans were evaluated for ILD-related radiologic abnormalities. Between-group differences were compared with non-parametric tests, while correlations with PFT parameters were analyzed using Spearman correlation coefficients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake was mainly increased in the dorsobasal lung fields of patients with SSc-ILD compared to SSc without ILD and controls (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03 and\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001, respectively).\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake was higher in SSc patients with extensive ILD (\u2265\u200920% vs\u2009&lt;\u200920%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04) and correlated with lower DLCO% (\n                      <jats:italic>R<\/jats:italic>\n                      \u2009=\u2009-0.59,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Ground-glass opacities, with or without reticulation, corresponded to increased\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT can detect metabolic activity in the lungs of patients with early severe diffuse cutaneous SSc and ILD, correlating with higher ILD extent (\u2265\u200920%) and lower DLCO%. These results suggest the potential utility of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET-CT in the early detection of ILD (progression) and aiding in risk stratification.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-024-03447-x","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T23:08:15Z","timestamp":1734563295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Quantitative 18F-FDG PET-CT can assess presence and extent of interstitial lung disease in early severe diffuse cutaneous systemic sclerosis"],"prefix":"10.1186","volume":"26","author":[{"given":"Bo","family":"Broens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther J.","family":"Nossent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian J.","family":"Meijboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben J. C.","family":"Zwezerijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Spierings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeska K.","family":"de Vries-Bouwstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob M.","family":"van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conny J.","family":"van der Laken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre E.","family":"Voskuyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"10103","key":"3447_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685\u201399.","journal-title":"Lancet"},{"issue":"10","key":"3447_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1136\/ard.2009.114264","volume":"69","author":"AJ Tyndall","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, Air\u00f2 P, Cozzi F, Carreira PE, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3447_CR3","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","volume":"8","author":"A Perelas","year":"2020","unstructured":"Perelas A, Silver RM, Arrossi AV, Highland KB. Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med. 2020;8(3):304\u201320.","journal-title":"Lancet Respir Med"},{"issue":"127","key":"3447_CR4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1183\/09059180.00005512","volume":"22","author":"JJ Solomon","year":"2013","unstructured":"Solomon JJ, Olson AL, Fischer A, Bull T, Brown KK, Raghu G. Scleroderma lung disease. Eur Respir Rev. 2013;22(127):6\u201319.","journal-title":"Eur Respir Rev"},{"issue":"12","key":"3447_CR5","doi-asserted-by":"publisher","first-page":"102978","DOI":"10.1016\/j.autrev.2021.102978","volume":"20","author":"MC Vonk","year":"2021","unstructured":"Vonk MC, Smith V, Sfikakis PP, Cutolo M, del Galdo F, Seibold JR. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmun Rev. 2021;20(12): 102978.","journal-title":"Autoimmun Rev"},{"issue":"26","key":"3447_CR6","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. NEJM. 2019;380(26):2518\u201328.","journal-title":"NEJM"},{"issue":"1","key":"3447_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","volume":"9","author":"KB Highland","year":"2021","unstructured":"Highland KB, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med. 2021;9(1):96\u2013106.","journal-title":"Lancet Respir Med"},{"issue":"10","key":"3447_CR8","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963\u201374.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3447_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"A-M Hoffmann-Vold","year":"2021","unstructured":"Hoffmann-Vold A-M, Allanore Y, Alves M, Brunborg C, Air\u00f3 P, Ananieva LP, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis. 2021;80(2):219\u201327.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"3447_CR10","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial Lung Disease in Systemic Sclerosis. Am J Respir Crit Care Med. 2008;177(11):1248\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 5","key":"3447_CR11","doi-asserted-by":"publisher","first-page":"v59","DOI":"10.1093\/rheumatology\/ken271","volume":"47","author":"AU Wells","year":"2008","unstructured":"Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford). 2008;47(Suppl 5):v59-61.","journal-title":"Rheumatology (Oxford)"},{"key":"3447_CR12","doi-asserted-by":"crossref","unstructured":"Bailey DL, Maisey MN, Townsend DW, Valk PE. Positron emission tomography. London: Springer; 2005.","DOI":"10.1007\/b136169"},{"issue":"5","key":"3447_CR13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.21037\/atm.2018.01.25","volume":"6","author":"S Volpi","year":"2018","unstructured":"Volpi S, Ali JM, Tasker A, Peryt A, Aresu G, Coonar AS. The role of positron emission tomography in the diagnosis, staging and response assessment of non-small cell lung cancer. Ann Transl Med. 2018;6(5):95.","journal-title":"Ann Transl Med"},{"issue":"3","key":"3447_CR14","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.ejrad.2010.01.021","volume":"73","author":"I Zerizer","year":"2010","unstructured":"Zerizer I, Tan K, Khan S, Barwick T, Marzola MC, Rubello D, Al-Nahhas A. Role of FDG-PET and PET\/CT in the diagnosis and management of vasculitis. Eur J Radiol. 2010;73(3):504\u20139.","journal-title":"Eur J Radiol"},{"issue":"12","key":"3447_CR15","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.ejrad.2016.10.001","volume":"85","author":"V Jacquelin","year":"2016","unstructured":"Jacquelin V, Mekinian A, Brillet PY, Nunes H, Fain O, Valeyre D, Soussan M. FDG-PET\/CT in the prediction of pulmonary function improvement in nonspecific interstitial pneumonia. A Pilot Study Eur J Radiol. 2016;85(12):2200\u20135.","journal-title":"A Pilot Study Eur J Radiol"},{"issue":"1","key":"3447_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/14397595.2015.1054099","volume":"26","author":"T Uehara","year":"2016","unstructured":"Uehara T, Takeno M, Hama M, Yoshimi R, Suda A, Ihata A, et al. Deep-inspiration breath-hold 18F-FDG-PET\/CT is useful for assessment of connective tissue disease associated interstitial pneumonia. Mod Rheumatol. 2016;26(1):121\u20137.","journal-title":"Mod Rheumatol"},{"issue":"4","key":"3447_CR17","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/annrheumdis-2018-213376","volume":"78","author":"S Bellando-Randone","year":"2019","unstructured":"Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, et al. 18F-fluorodeoxyglucose positron-emission tomography\/CT and lung involvement in systemic sclerosis. Ann Rheum Dis. 2019;78(4):577\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3447_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/rheumatology\/kez483","volume":"59","author":"DM Peelen","year":"2020","unstructured":"Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, Voskuyl AE. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology. 2020;59(6):1407\u201315.","journal-title":"Rheumatology"},{"issue":"1","key":"3447_CR19","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13075-021-02460-8","volume":"23","author":"E Ledoult","year":"2021","unstructured":"Ledoult E, Morelle M, Soussan M, M\u00e9kinian A, B\u00e9hal H, Sobanski V, et al. (18)F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study. Arthritis Res Ther. 2021;23(1):76.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"3447_CR20","doi-asserted-by":"publisher","first-page":"e044483","DOI":"10.1136\/bmjopen-2020-044483","volume":"11","author":"J Spierings","year":"2021","unstructured":"Spierings J, van Rhenen A, Welsing PMW, Marijnissen ACA, De Langhe E, Del Papa N, et al. A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open. 2021;11(3): e044483.","journal-title":"BMJ Open"},{"issue":"2","key":"3447_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328\u201354.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"supplement 1","key":"3447_CR22","first-page":"1753-","volume":"59","author":"R Boellaard","year":"2018","unstructured":"Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE. J Nucl Med. 2018;59(supplement 1):1753-.","journal-title":"J Nucl Med."},{"issue":"5","key":"3447_CR23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2967\/jnumed.112.108530","volume":"54","author":"RR Boktor","year":"2013","unstructured":"Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med. 2013;54(5):677\u201382.","journal-title":"J Nucl Med"},{"issue":"9","key":"3447_CR24","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18\u201347.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"3447_CR25","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/art.39166","volume":"67","author":"A-M Hoffmann-Vold","year":"2015","unstructured":"Hoffmann-Vold A-M, Aal\u00f8kken TM, Lund MB, Garen T, Midtvedt \u00d8, Brunborg C, et al. Predictive Value of Serial High-Resolution Computed Tomography Analyses and Concurrent Lung Function Tests in Systemic Sclerosis. Arthritis & Rheumatology. 2015;67(8):2205\u201312.","journal-title":"Arthritis & Rheumatology"},{"issue":"3","key":"3447_CR26","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1148\/radiol.2462070712","volume":"246","author":"DM Hansell","year":"2008","unstructured":"Hansell DM, Bankier AA, MacMahon H, McLoud TC, M\u00fcller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697\u2013722.","journal-title":"Radiology"},{"issue":"1","key":"3447_CR27","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","volume":"52","author":"OA Moore","year":"2012","unstructured":"Moore OA, Goh N, Corte T, Rouse H, Hennessy O, Thakkar V, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology. 2012;52(1):155\u201360.","journal-title":"Rheumatology"},{"issue":"8","key":"3447_CR28","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.40130","volume":"69","author":"NS Goh","year":"2017","unstructured":"Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis Rheumatol. 2017;69(8):1670\u20138.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"3447_CR29","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.autrev.2018.02.008","volume":"17","author":"S Panopoulos","year":"2018","unstructured":"Panopoulos S, Bournia V-K, Konstantonis G, Fragiadaki K, Sfikakis PP, Tektonidou MG. Predictors of morbidity and mortality in early systemic sclerosis: Long-term follow-up data from a single-centre inception cohort. Autoimmun Rev. 2018;17(8):816\u201320.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"3447_CR30","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s41824-018-0045-z","volume":"2","author":"A Castiaux","year":"2018","unstructured":"Castiaux A, Van Simaeys G, Goldman S, Bondue B. Assessment of 18F-FDG uptake in idiopathic pulmonary fibrosis: influence of lung density changes. Eur J Hybrid Imaging. 2018;2(1):27.","journal-title":"Eur J Hybrid Imaging"},{"issue":"3","key":"3447_CR31","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/1346-8138.14758","volume":"46","author":"SI Motegi","year":"2019","unstructured":"Motegi SI, Fujiwara C, Sekiguchi A, Hara K, Yamaguchi K, Maeno T, et al. Clinical value of (18) F-fluorodeoxyglucose positron emission tomography\/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. J Dermatol. 2019;46(3):213\u20138.","journal-title":"J Dermatol"},{"issue":"3","key":"3447_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s12149-009-0234-8","volume":"23","author":"K Inoue","year":"2009","unstructured":"Inoue K, Okada K, Taki Y, Goto R, Kinomura S, Fukuda H. (18)FDG uptake associated with CT density on PET\/CT in lungs with and without chronic interstitial lung diseases. Ann Nucl Med. 2009;23(3):277\u201381.","journal-title":"Ann Nucl Med"},{"issue":"4","key":"3447_CR33","doi-asserted-by":"publisher","first-page":"538","DOI":"10.2967\/jnumed.108.057901","volume":"50","author":"AM Groves","year":"2009","unstructured":"Groves AM, Win T, Screaton NJ, Berovic M, Endozo R, Booth H, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET\/CT. J Nucl Med. 2009;50(4):538\u201345.","journal-title":"J Nucl Med"},{"issue":"1","key":"3447_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","volume":"18","author":"A Justet","year":"2017","unstructured":"Justet A, Laurent-Bellue A, Thabut G, Dieudonn\u00e9 A, Debray MP, Borie R, et al. [(18)F]FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):74.","journal-title":"Respir Res"},{"issue":"12","key":"3447_CR35","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.116.174946","volume":"57","author":"T Nobashi","year":"2016","unstructured":"Nobashi T, Kubo T, Nakamoto Y, Handa T, Koyasu S, Ishimori T, et al. 18F-FDG Uptake in Less Affected Lung Field Provides Prognostic Stratification in Patients with Interstitial Lung Disease. J Nucl Med. 2016;57(12):1899\u2013904.","journal-title":"J Nucl Med"},{"issue":"6","key":"3447_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MNM.0000000000000083","volume":"35","author":"EY Lee","year":"2014","unstructured":"Lee EY, Wong CS, Fung SL, Yan PK, Ho JC. SUV as an adjunct in evaluating disease activity in idiopathic pulmonary fibrosis - a pilot study. Nucl Med Commun. 2014;35(6):631\u20137.","journal-title":"Nucl Med Commun"},{"issue":"5","key":"3447_CR37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1183\/09031936.00069307","volume":"30","author":"TM Maher","year":"2007","unstructured":"Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007;30(5):835\u20139.","journal-title":"Eur Respir J"},{"issue":"3","key":"3447_CR38","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2665-9913(20)30421-5","volume":"3","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, Distler JHW, Treutlein C, Tascilar K, M\u00fcller A-T, Atzinger A, et al. 68Ga-FAPI-04 PET-CT for molecular assessment of fibroblast activation and risk evaluation in systemic sclerosis-associated interstitial lung disease: a single-centre, pilot study. The Lancet Rheumatology. 2021;3(3):e185\u201394.","journal-title":"The Lancet Rheumatology"},{"issue":"4","key":"3447_CR39","first-page":"168","volume":"10","author":"H Adams","year":"2020","unstructured":"Adams H, Meek B, van de Garde EM, van Moorsel CH, Vugts DJ, Keijsers RG, Grutters JC. Altered splenic [(89)Zr]Zr-rituximab uptake in patients with interstitial lung disease not responding to rituximab: could this indicate a splenic immune-mediated mechanism? Am J Nucl Med Mol Imaging. 2020;10(4):168\u201377.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"6","key":"3447_CR40","first-page":"296","volume":"9","author":"H Adams","year":"2019","unstructured":"Adams H, van de Garde EM, van Moorsel CH, Vugts DJ, van Dongen GA, Grutters JC, Keijsers RG. [(89)Zr]Zr-rituximab PET\/CT activity in patients with therapy refractory interstitial pneumonitis: a feasibility study. Am J Nucl Med Mol Imaging. 2019;9(6):296\u2013308.","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"4","key":"3447_CR41","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00259-019-04586-z","volume":"47","author":"PT Lukey","year":"2020","unstructured":"Lukey PT, Coello C, Gunn R, Parker C, Wilson FJ, Saleem A, et al. Clinical quantification of the integrin \u03b1v\u03b26 by [(18)F]FB-A20FMDV2 positron emission tomography in healthy and fibrotic human lung (PETAL Study). Eur J Nucl Med Mol Imaging. 2020;47(4):967\u201379.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"3447_CR42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.nucmedbio.2008.10.001","volume":"35","author":"HM Branley","year":"2008","unstructured":"Branley HM, du Bois RM, Wells AU, Jones HA. PET scanning of macrophages in patients with scleroderma fibrosing alveolitis. Nucl Med Biol. 2008;35(8):901\u20139.","journal-title":"Nucl Med Biol"},{"key":"3447_CR43","doi-asserted-by":"crossref","unstructured":"Grootjans W, Rietbergen DDD, van Velden FHP. Added Value of Respiratory Gating in Positron Emission Tomography for the Clinical Management of Lung Cancer Patients. Semin Nucl Med. 2022;52(6):745\u201358.","DOI":"10.1053\/j.semnuclmed.2022.04.006"},{"issue":"3","key":"3447_CR44","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/1754-9485.12154","volume":"58","author":"AK Tahari","year":"2014","unstructured":"Tahari AK, Lodge MA, Wahl RL. Respiratory-gated PET\/CT versus delayed images for the quantitative evaluation of lower pulmonary and hepatic lesions. J Med Imaging Radiat Oncol. 2014;58(3):277\u201382.","journal-title":"J Med Imaging Radiat Oncol"},{"issue":"6","key":"3447_CR45","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.semnuclmed.2022.04.004","volume":"52","author":"R Manafi-Farid","year":"2022","unstructured":"Manafi-Farid R, Askari E, Shiri I, Pirich C, Asadi M, Khateri M, et al. [18F]FDG-PET\/CT Radiomics and Artificial Intelligence in Lung Cancer: Technical Aspects and Potential Clinical Applications. Semin Nucl Med. 2022;52(6):759\u201380.","journal-title":"Semin Nucl Med"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03447-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03447-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T01:05:23Z","timestamp":1734570323000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03447-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3447"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03447-x","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The medical ethics committees of all participating centers approved the study. All patients and controls have provided oral and written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"219"}}